UFP Technologies, Inc.
UFPT
Positions held
Your positionsUFPT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- UFP Technologies is well-positioned in the growing medical devices industry, benefiting from increasing demand for innovative healthcare solutions.
- Revenue increased by 13% compared to the prior quarter, reaching $174 million.
- Gross margin improved to 29.3%, up from 28.8% in the previous quarter.
- The company's high trailing P/E ratio of 32.71 may indicate overvaluation compared to industry peers.
- The debt-to-equity ratio stands at 29.48, suggesting potential financial risk.
- The PEG ratio of 3.8 indicates that the stock may be expensive relative to its earnings growth.
Fundamentals
| Market cap | $2.22B | Enterprise value | $2.35B | Trailing P/E | 30.95 | Forward P/E | 24.14 |
| PEG | 3.80 | Price / book | 4.80 | Beta | 1.03 | Dividend yield | 0.00% |
| Revenue growth | 15.1% | Earnings growth | 21.3% | Gross margin | 28.5% | Operating margin | 16.2% |
| Profit margin | 11.4% | ROE | 17.1% | ROA | 9.1% | Debt / equity | 0.29 |
| Current ratio | 3.00 | Free cash flow | $34.87M | Analyst recommendation | none | Mean target | $355.00 |
| 52w high | $338.71 | 52w low | $173.86 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $174M | $154M | $149M | $155M | $151M |
| Op margin | 16.2% | 15.1% | 14.1% | 15.3% | 16.4% |
| Net income | $20.9M | $17.5M | $17.6M | $16.4M | $17.2M |
| Gross margin | 29.3% | 28.8% | 28.2% | 27.7% | 28.8% |
| Gross profit | $50.9M | $44.4M | $42.0M | $42.7M | $43.5M |
| Operating income | $28.2M | $23.3M | $21.0M | $23.7M | $24.9M |
- Revenue +13% vs prior quarter ($174M vs $154M).
- Gross margin 29.3% (was 28.8% prior quarter).
- Operating margin expanded to 16.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $603M | $504M | $400M | $354M | — |
| Op margin | 15.4% | 16.7% | 15.3% | 12.6% | — |
| Net income | $68.3M | $59.0M | $44.9M | $41.8M | — |
| Gross margin | 28.3% | 29.1% | 28.1% | 25.5% | — |
| Gross profit | $170M | $147M | $112M | $90.3M | — |
| Operating income | $93.0M | $84.5M | $61.3M | $44.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment
2026-09-28 · H.B. Fuller Appoints R. Jeffrey Bailly to Board of Directors
2026-09-26 · UFP Technologies (UFPT) Stock Looks Rich Despite Its 378% Five Year Run
2026-09-25 · Labor Problems Pressured UFP Technologies (UFPT)
2026-09-21 · 3 Russell 2000 Stocks That Concern Us
2026-09-18 · 1 Cash-Producing Stock for Long-Term Investors and 2 We Find Risky
2026-09-10 · Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies
2026-09-09 · Implied Volatility Surging for UFP Technologies Stock Options
2026-09-09 · 3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes
2026-09-03 · UFP Technologies (UFPT) Posts Record Profits, But The Margin Story Gets Complicated
2026-08-31 · UFP Technologies Director Cynthia Feldmann Sells 1,000 Shares
2026-08-28 · UFP Technologies Targets 12%-18% Growth as Medical Device M&A Pipeline Builds
Price (daily)
Full chart · RSI · MACD · patterns